Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian Cancer

Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.

Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer. Matulonis says the trials, dubbed NRG-GY004 and NRG-GY005, look at the combination of cediranib and olaparib in both platinum-sensitive and platinum-resistant recurrent ovarian cancer after a successful phase II looking at the combination against olaparib as a single agent.